FDA panel issues mixed decision on quetiapine in depression and anxiety.
Kuehn
Bridget M
BM
D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001008:Anxiety Disorders / Q000188:drug therapy; D003865:Major Depressive Disorder / Q000188:drug therapy; D003987:Dibenzothiazepines / Q000009:adverse effects* / Q000627:therapeutic use; D017277:Drug Approval; D006801:Humans; D000069348:Quetiapine Fumarate; D014481:United States; D014486:United States Food and Drug Administration
D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate